This approval represents the seventh FDA-approved companion diagnostic indication for PD-L1 IHC 22C3 pharmDx with KEYTRUDA
MYC, a master regulator of oncogenic transcription, drives multiple high-burden cancers but has long eluded direct pharmacologic control
Bocunebart works by blocking pituitary adenylate cyclase-activating polypeptide
ADQUEY’s approval opens the door to a new alternative for millions of Americans struggling with atopic dermatitis
The milestone means more than 1,000 men are now enrolled across both Phase 3 programs
Anand Chemiceutics serves over 1,500 laboratories, hospitals, and government institutions
Subscribe To Our Newsletter & Stay Updated